1. Fig. 1 HSCT: A platform for cellular therapies.
HSCT: A platform for cellular therapies. The major biological determinants of clinical outcome after HSCT are the ability of HSCs to regenerate the host hematopoietic system and the immunological events associated with the procedure in the case of allogeneic donors: the beneficial effects of graft-versus-leukemia (GVL) and graft-versus-infection (GVI) and the detrimental effects of GVHD and rejection. Cellular therapy approaches relying on the regenerative capacity of stem cells have also stemmed from HSCT in recent years and have been tested in clinical trials to treat congenital and acquired diseases. In addition, specific cell-based immunotherapy approaches have been designed to boost graft-versus-tumor (GVT) and GVI and to promote immunological tolerance, thus controlling both GVHD and graft rejection. NK, natural killer cells; NKT, natural killer T cells.
Christian Chabannon et al., Sci Transl Med 2018;10:eaap9630
Published by AAAS